S&P 500 7,498.96 -0.14% NASDAQ 25,690.90 -0.57% DOW 52,218.58 -0.01% R2K 2,959.94 -0.92% VIX 18.91 +13.64% US 10Y 4.70 +1.03% DXY 101.39 +0.25% GOLD 4,060.80 -2.08% CRUDE 91.28 +5.12% BITCOIN 65,028.85 -1.62%
Next Bullish Trade
Sign in
TAK

TAK TAK

$16.87 -0.36 (-2.09%)
Extended · +1.08σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · TAK

Momentum reads · latest daily bar
Last
$16.87
-0.36 (-2.09%)
Mkt cap
$53.9B
Healthcare
RSI(14)
57.8
neutral
Stochastic %K
82.2
overbought
MFI(14)
47.0
neutral
ADX(14)
22.1
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $1,094.5B $-368.5B $42.1B $10.1B -33.7% 3.8%
2025-12-31 $1,191.7B $103.6B $168.8B $150.9B 8.7% 14.2%
2025-09-30 $1,112.8B $-11.8B $69.0B $325.4B -1.1% 6.2%
2025-06-30 $1,106.7B $124.2B $184.6B $140.4B 11.2% 16.7%
2025-03-31 $1,053.4B $-103.2B $68.5B $129.4B -9.8% 6.5%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare TAK vs peers

Line TAK up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing TAK no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with TAK

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 9 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2023-07-27 28.76 18.62 +54.4% -1.9%
2022-10-27 20.03 67.54 -70.3% +1.2%
2022-07-28 33.97 59.27 -42.7% -1.4%
2021-10-28 -5.13 97.00 -105.3% -0.6%
2021-07-30 64.00 95.00 -32.6% +1.4%
2021-05-11 63.08 88.00 -28.3% —
2021-02-04 29.78 105.00 -71.6% —
2020-10-29 1.38 103.00 -98.7% —
2020-07-31 26.35 85.00 -69.0% —

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
TAK ★ $54B — 31.8 0.0 4.0 1.2 64.1% 3.9% — 1248.80%
LLY $1,037B 41.3 25.9 — 29.7 33.3 82.8% 55.5% 169.9% 0.88%
UNH $392B 32.5 19.2 0.9 17.9 3.7 19.5% 0.4% 61.5% 5.81%
JNJ $615B 29.7 19.9 6.3 18.6 7.6 68.1% 6.6% -1.0% —
MRK $315B 35.6 13.2 — 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $448B 123.6 15.6 7.1 17.1 -67.2 72.0% 12.4% -46.2% 4.65%
PFE $141B 18.9 8.8 — 7.6 1.6 74.8% 5.4% -10.1% 8.75%
TMO $196B 28.9 19.3 — 20.9 3.8 40.9% 6.2% 11.3% 2.82%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 1.92%

HolderShares% out
Capital Research Global Investors 19,104,219 0.60%
FMR, LLC 7,117,486 0.22%
Adage Capital Partners GP L.L.C. 6,424,984 0.20%
Morgan Stanley 6,469,600 0.20%
Goldman Sachs Group Inc 5,618,728 0.18%
Brandes Investment Partners L.P. 4,430,642 0.14%
Blackrock Inc. 3,176,421 0.10%
Arrowstreet Capital, Limited Partner 3,116,311 0.10%
UBS Group AG 2,740,229 0.09%
Renaissance Technologies, LLC 2,989,100 0.09%

Insider activity · 90d

8 buys / 7 sells · ratio 1.14 · Finnhub

  • Reed Kimberly A. SELL 0 @ $4931.20
  • Iijima Masami SELL 0 @ $4931.20
  • Tsusaka Miki SELL 0 @ $4931.20
  • Miyabashira Asuka SELL 0 @ $4931.40
  • Furuta Milano SELL 0 @ $4931.50
  • GILLIS STEVEN SELL 0 @ $4931.20
  • MARAGANORE JOHN SELL 0 @ $4931.20
  • Reed Kimberly A. BUY 1,319
  • Reed Kimberly A. BUY 10,400
  • Iijima Masami BUY 1,937

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$19.006268
Mean
$20.856718
High
$22.828468
Analysts
3
Recommendation distribution · period 2026-07-01
5
8
6
Revision trend (2026-04-01 → 2026-07-01): net 11 → 13 +2 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-07-06 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2026-04-28 FORM 4 view ·
4 2025-12-09 FORM 4 view ·
13F-HR 2025-11-13 Institutional holdings (13F) view ·
4 2025-09-19 FORM 4 view ·
13F-HR 2025-08-08 Institutional holdings (13F) view ·
13F-HR 2025-05-12 Institutional holdings (13F) view ·
13F-HR 2025-02-13 Institutional holdings (13F) view ·
13F-HR 2025-02-13 Institutional holdings (13F) view ·
13F-HR 2025-02-13 Institutional holdings (13F) view ·
13F-HR 2025-02-13 Institutional holdings (13F) view ·
13F-HR 2025-02-12 Institutional holdings (13F) view ·
4 2024-01-25 FORM 4 view ·
4 2023-05-26 FORM 4 view ·
4 2022-12-01 FORM 4 view ·
4 2022-07-06 FORM 4 view ·
4 2022-07-06 FORM 4 view ·
4 2022-03-16 FORM 4 view ·
4 2021-12-09 FORM 4 view ·
4 2021-12-07 FORM 4 view ·
4 2021-11-29 FORM 4 view ·
4 2021-11-08 FORM 4 view ·
4 2021-10-26 FORM 4 view ·
4 2021-10-15 FORM 4 view ·
4 2021-07-09 FORM 4 view ·
4 2021-07-06 FORM 4 view ·
4 2021-06-29 FORM 4 view ·
4 2021-06-25 FORM 4 view ·
4 2021-06-23 FORM 4 view ·

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnso…

Options picks · TAK

ITM + OTM ideas from the latest scan

Loading…

Congress trades · TAK

STOCK Act disclosures

Loading…

SEC filings & insiders · TAK

EDGAR · live

Loading…

Holders · TAK

Institutions & insider activity

Loading…